Abstract:Objective: To investigate the analytical performance verification protocols and performance specifications of platelet-dependent von Willebrand factor (VWF) activity testing (VWF:GPIbM) for clinical laboratories. Methods: According to Clinical Laboratory Standards Institute (CLSI) documents and National Health Standard of China, the performance verification of VWF:GPIbM was designed and implemented using Sysmex CS-5100 instrument and its corresponding reagents. (1) Precision verification: Two commercial quality control samples (with normal and low activity levels) and three plasma pools (with activity range from 5.0% to 150.0%) were prepared. Each sample was tested five times daily for five consecutive days. The coefficient of variation (CV) of intra-and inter-run precisions were calculated, and the precision evaluation criterion was set according to package inserts. (2) Trueness verification: The calibrator was diluted to five reference materials with activity values of 5.2%, 31.2%, 62.4%, 104.0% and 138.7%, and each reference material was tested five times daily for five consecutive days. The bias between the measured value and the reference value was calculated, and the trueness evaluation criterion was set according to the total allowable error. (3) Linearity verification: Ten pooled plasmas with theoretical value range from 3.6% to 160.4% were prepared for the linearity verification of two calibration curves set by the manufacturer (i.e. low range and normal range calibration curve). Each pooled plasma was tested three times in a single run. The slope and R2 of linear regression of mean of measured value and theoretical value, as well as bias, were calculated, and the linearity evaluation criterion was set according to National Health Standard of China and package inserts. (4) Limit of quantitation verification: The calibrator was diluted to two reference materials with activity values of 3.3% and 2.7%, and each material was tested twelve times. The limit of quantitation evaluation criterion was set according to CLSI document. Results: The CVs of intra-and inter-run were 1.0%-2.5% and 1.1%-2.6%, respectively. The biases of trueness verification were -0.4%, 1.0%, -2.6%, 0.3% and -2.7%, respectively. The linearity verification results of low range (3.6%-31.8%) and normal range (28.4%-160.4%) showed that the slopes of regression equation were 1.021 7 and 0.996 2, respectively, R2 were 0.993 5 and 0.993 9, respectively, and the biases with 0-1.8% and -10.1%-0 of plasmas met the criterion. The biases ranged from -0.4% to 0.3% of test results in the verification of limit of quantitation met the criterion. Conclusion: The verification results of VWF:GPIbM assay for precision, trueness, linearity and limit of quantification meet the performance requirements indicated in the package inserts and the criteria set in this study, which can be taken as a reference of performance verification for the clinical laboratories.

The Comparison Study of Four Kinds of Tests for Diagnosis of Von Willebrand Disease

[Application of Collagen-Binding Assay for Von Willebrand Disease].

Development and Clinical Application of Diagnostic Tests for Von Willebrand Disease

Development Of An Elisa Method For Testing Vwf Ristocetin Cofactor Activity With Improved Sensitivity And Reliability In The Diagnosis Of Von Willebrand Disease

Differences of Quality and Quantity of the von Willebrand Factor on the ABO Blood Group in Laboratory Parameters

Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.

Application of von Willebrand Factor Antigen test in the Differential Diagnosis of von Willebrand Disease and Hemophilia A

The New Diagnostic Test of Vwd2n

Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD

Does the VWF:CB Assay Help to Diagnose von Willebrand Factor Deficiency in Patients With a Bleeding Disorder of Unknown Cause?

Molecular diagosis of von Willebrand disease

Analytical and Clinical Validation of a Non-Ristocetin Based VWF Assay on 2 Automated Analyzers in a Large Reference Laboratory

Evaluation of Laboratory Tests in Diagnosis of Used for Thrombotic Diseases

Establishment of variables-specific reference ranges of von Willebrand factor antigen and activity

[Analytical Performance Verification Protocols and Performance Specifications of Platelet-Dependent Von Willebrand Factor Activity Testing].

Establishment and Clinical Application of Flow Cytometric Immunobead Array in Detecting Plasma Von Willebrand Factor Antigen

Development of a novel flow cytometric immunobead array to quantify VWF: Ag and VWF: GPIbR and its application in acute myocardial infarction.

[Detection and Analysis of Plasma VWF Levels in Healthy Chinese by Automatic Standardized Assay].

Biological Variations of Lupus Anticoagulant, Antithrombin, Protein C, Protein S, and von Willebrand Factor Assays.

The Phenotypic and Genotypic Diagnosis of Three Chinese Patients with Von Willebrand Disease

Clinical application evaluation of chromogenic substrate assay in detecting coagulation factor Ⅷ activity